Finally, TD Cowen restated a “buy” rating and issued a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Six equities research ...

Guggenheim restated a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. TD Cowen restated a “buy” rating and issued a $74.00 target price (up from $58.00 ...

The five-year extension of its Google agreement further supports AI development. TD Cowen’s Daniel Brennan reiterated a Buy rating on Tempus AI Inc. (NASDAQ:TEM) on February 24, while setting a ...

The five-year extension of its Google agreement further supports AI development. TD Cowen’s Daniel Brennan reiterated a Buy rating on Tempus AI Inc. (NASDAQ:TEM) on February 24, while setting a ...

SAN DIEGO and CHICAGO - Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ ... the next-generation sequencing market. Meanwhile, TD Cowen has adjusted its price target for Illumina to ...

On Tuesday, Loop Capital initiated coverage on Tempus AI Inc (NASDAQ:TEM) stock, assigning a Buy rating to the company with a... Tuesday - Analysts at TD Cowen have initiated coverage on Tempus AI ...

SAN DIEGO and CHICAGO - Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ ... about challenges in the next-generation sequencing market. Meanwhile, TD Cowen has adjusted its price target for ...

HEAL seeks to provide investors exposure to the growing HealthTech industry, which is expected to grow fourfold from $225 billion in 2022 to over $1 trillion by 2032.